D-type cyclins (D1, D2 and D3) and their associated cyclindependent kinases (CDK4 and CDK6) are components of the core cell cycle machinery that drives cell proliferation 1,2 . Inhibitors of CDK4 and CDK6 are currently being tested in clinical trials for patients with several cancer types, with promising results 2 . Here, using human cancer cells and patient-derived xenografts in mice, we show that the cyclin D3-CDK6 kinase phosphorylates and inhibits the catalytic activity of two key enzymes in the glycolytic pathway, 6-phosphofructokinase and pyruvate kinase M2. This re-directs the glycolytic intermediates into the pentose phosphate (PPP) and serine pathways. Inhibition of cyclin D3-CDK6 in tumour cells reduces flow through the PPP and serine pathways, thereby depleting the antioxidants NADPH and glutathione. This, in turn, increases the levels of reactive oxygen species and causes apoptosis of tumour cells. The pro-survival function of cyclin D-associated kinase operates in tumours expressing high levels of cyclin D3-CDK6 complexes. We propose that measuring the levels of cyclin D3-CDK6 in human cancers might help to identify tumour subsets that undergo cell death and tumour regression upon inhibition of CDK4 and CDK6. Cyclin D3-CDK6, through its ability to link cell cycle and cell metabolism, represents a particularly powerful oncoprotein that affects cancer cells at several levels, and this property can be exploited for anti-cancer therapy.
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D-type cyclins (D1, D2 and D3) are components of the core cell cycle machinery that activate the cyclin-dependent kinases CDK4 and CDK6, and are often overexpressed in human cancers 1-3. Inhibition of cyclin D-CDK4/6 kinase in retinoblastoma protein (RB1)-proficient cancer cells causes cell cycle arrest and, in some cases, cellular senescence 4, 5 . By contrast, tumour cells that have lost RB1 do not halt their proliferation upon inhibition of CDK4 and CDK6, consistent with the notion that RB1 represents the rate-limiting substrate of cyclin D-CDK4/6 in cell cycle progression 6 . However, in case of T-cell acute lymphoblastic leukaemia (T-ALL), acute genetic shutdown of cyclin D3, or inhibition of cyclin D-CDK4/6 kinase, triggers apoptosis of tumour cells 7, 8 . The molecular basis of this pro-survival function of cyclin D3-CDK4/6 has remained unknown.
Analysis of the expression of D-type cyclins, CDK4 and CDK6 in human T-ALL cells showed that this tumour type expresses predominantly cyclin D3 and CDK6, and abundant cyclin D3-CDK6 complexes, but low levels of cyclins D1 and D2 and CDK4 (Extended Data Fig. 1a-c) . Like inhibition of cyclin D-CDK4/6 kinase, depletion of cyclin D3 or CDK6 triggered T-ALL cell death (Extended Data Fig. 1d-h ). Unexpectedly, inhibition of CDK4/6 also caused apoptosis in T-ALL cells that lacked RB1 and the RB1-related RBL1 and RBL2 (Extended Data Fig. 1i-l) . Hence, we hypothesized that cyclin D3-CDK6 kinase promotes cancer cell survival through phosphorylation of other substrates.
To search for cyclin D3-CDK6 substrates in T-ALL cells, we immunoprecipitated endogenous CDK6 from three human T-ALL cell lines and identified the associated proteins using mass spectrometry (Supplementary Table 1 ). Gene Ontology analyses of CDK6 interactors that were commonly identified in all three T-ALL cell lines revealed that carbohydrate metabolism and glycolysis were the only significantly (P < 0.01) enriched functions (Fig. 1a and Supplementary Table 2) . Indeed, out of eleven enzymes that are involved in glycolysis, ten bound to CDK6 (Supplementary Table 1 ) and nine of these represent potential CDK substrates (Supplementary Table 3 ). Two of these enzymes, 6-phosphofructokinase (PFK1) and pyruvate kinase M2 (PKM2), catalyse irreversible and rate-limiting steps in glycolysis, and have been shown to play important roles in reprogramming cancer cell metabolism [9] [10] [11] . Therefore, we focused on the regulation of these two key enzymes by cyclin D3-CDK6.
We first established that human T-ALL cells express the PFKP isoform of PFK1 and the PKM2 isoform of pyruvate kinase (Extended Data Fig. 1m-o) , and that CDK6 interacts physically with PFKP and PKM2 in the five human T-ALL cell lines analysed (Extended Data  Fig. 1p , q and data not shown).
In vitro kinase reactions revealed that all three PFK1 isoforms (PFKP, PFKL and PFKM) and PKM2 were phosphorylated by cyclin D3-CDK6 (Extended Data Fig. 2a-c) . Using mass spectrometry, we identified cyclin D3-CDK6-dependent phosphoresidues on PFK1 and PKM2 (Extended Data Fig. 2d and Supplementary Table 4 ). In addition, endogenous CDK6 immunoprecipitated from T-ALL cells was able to phosphorylate recombinant PFKP and PKM2, and this reaction was extinguished by the CDK4/6 inhibitor palbociclib 2 (Fig. 1b) . Moreover, depletion of cyclin D3 or CDK6, or inhibition of cyclin D3-CDK6 kinase, diminished phosphorylation of endogenous PFKP and PKM2 ( Fig. 1c and Extended Data Fig. 2e-k) . Importantly, other types of cyclin D-CDK4/6 complex tested were less efficient in phosphorylating PFKP, PFKL, PFKM and PKM2 (Extended Data Fig. 2a, b) . These findings suggest that cyclin D3-CDK6 may carry out a unique role in glucose metabolism by directly phosphorylating two key glycolytic enzymes.
We next determined that phosphorylation of PFKP and PKM2 by cyclin D3-CDK6 inhibits their enzymatic activities. Preincubation of recombinant PFKP or PKM2 with cyclin D3-CDK6 decreased the enzymatic activity of these proteins (Extended Data Fig. 3a, b) . Phosphomimicking mutants of PFKP (S679E) or PKM2 (S37E) displayed decreased catalytic activity, which was not further affected by preincubation with cyclin D3-CDK6 (Extended Data Fig. 3a, b) . Moreover, ectopic overexpression of cyclin D3 and CDK6, but not cyclin D3 together with a kinase-dead CDK6 mutant, in human tumour cells decreased the enzymatic activity of endogenous PFKP and PKM2 (Fig. 1d) . Conversely, depletion of cyclin D3 or CDK6, or treatment of human T-ALL cell lines with palbociclib, resulted in increased activity of endogenous PFKP and PKM2 ( Fig. 1e and Extended Data Fig. 3c, d ). Collectively, these findings indicate that cyclin D3-CDK6 negatively regulates PFKP and PKM2 through direct phosphorylation.
The cyclin D3-CDK6-dependent phosphorylation site on PFK1 is adjacent to the activating allosteric ADP-binding site 12, 13 . Preincubation of recombinant PFKP with cyclin D3-CDK6 decreased binding of ADP to PFKP (Extended Data Fig. 3e) . A phosphomimicking PFKP mutant displayed a reduced ability to bind ADP, and its ADP binding was not affected by preincubation with cyclin D3-CDK6 (Extended Data Fig. 3e-g ).
ADP binding activates PFK1 enzymatic activity by promoting formation of catalytically active PFK1 tetramers at the expense of less active dimers 14 . Consistent with reduced ADP binding, the phosphomimicking PFKP S679E mutant displayed an increased fraction of dimeric complexes (Extended Data Fig. 3h, i ) and the size of native PFKP complexes in vivo was decreased (Extended Data Fig. 3j, k) . In agreement with these findings, treatment of T-ALL cells with palbociclib resulted in an increase in the size of the endogenous PFKP complexes (Extended Data Fig. 3l, m) . Hence, cyclin D3-CDK6-dependent phosphorylation of PFKP inhibits PFKP by decreasing ADP binding to an allosteric regulatory site, which impedes formation of enzymatically active PFKP tetramers.
Similarly, PKM2 exists in catalytically active tetrameric and less active dimeric forms 15 . A phosphomimicking PKM2 mutant showed strongly impaired formation of tetramers and an increased fraction of dimers (Extended Data Fig. 3n, o) . Moreover, treatment of T-ALL cells with palbociclib resulted in an increase in the size of the endogenous PKM2 complexes (Extended Data Fig. 3l, m) . Collectively, these observations indicate that cyclin D3-CDK6-dependent phosphorylation of PKM2 reduces the enzymatic activity of PKM2 by preventing the formation of tetramers.
A reduction in the activity of the rate-limiting glycolytic enzymes PFK1 and PKM2 in cancer cells re-directs glycolytic intermediates into the pentose phosphate (PPP) and serine synthesis pathways [16] [17] [18] [19] . PPP is the predominant source of the reduced form of nicotinamide adenine dinucleotide phosphate (NADPH), that, with glutathione, provides a major cellular defence mechanism against reactive oxygen species (ROS) 9 . The serine pathway also contributes to NADPH production via serine-driven one-carbon metabolism, and generates the glutathione precursors glycine and cysteine 20 . Given our observation that cyclin D3-CDK6 impedes the activity of PFK1 and PKM2 in tumour cells, inhibition of cyclin D3-CDK6 would be expected to reduce carbon flow into the PPP and serine pathways, thereby resulting in decreased NADPH and glutathione production. To test this prediction, we treated human T-ALL cell lines with palbociclib in the presence of [1,2- 13 C]glucose and quantified the flow of 13 C using isotopic enrichment analysis and mass spectrometry. Inhibition of cyclin D3-CDK6 decreased the flow of glucose-derived carbon into the PPP and serine pathways (Fig. 2a, b and Extended Data Fig. 4a-d) . Moreover, treatment with palbociclib, or depletion of cyclin D3 or CDK6 in T-ALL cells, decreased the levels of NADPH ( Fig. 2c and Extended Data Fig. 4e ) and of reduced glutathione (GSH; Fig. 2d and Extended Data Fig. 4f ), and resulted in increased ROS levels ( Fig. 2e and Extended Data Fig. 4g ). Importantly, treatment of T-ALL cells with an antioxidant N-acetyl-cysteine (NAC) or with a cell-permeable superoxide dismutase mimetic (MnTMPyP) blocked the increase in ROS levels upon palbociclib treatment (Extended Data Fig. 4h , i) and protected T-ALL cells against palbociclib-induced apoptosis ( Fig. 2f and Extended Data Fig. 4j ), suggesting a causative link between increased ROS levels induced by cyclin D3-CDK6 inhibition and tumour cell death.
To test whether the metabolic effects of palbociclib are caused by altered phosphorylation of PFK1 and PKM2, we engineered human T-ALL cells to express-in place of wild-type PFKP and PKM2-mutant PFKP and PKM2 containing phosphomimicking substitutions within cyclin D3-CDK6-dependent residues (Extended Data Figs 5a, 6a-i). Inhibition of CDK4/6 in cells expressing both phosphomimicking PFKP and PKM2 mutants did not increase the activity of these enzymes, and did not increase the sizes of PFKP and PKM2 complexes, unlike in parental cells (Extended Data Fig. 5b-g ). Furthermore, cyclin D3-CDK6 inhibition in these cells did not significantly reduce carbon flow into the PPP and serine pathways (Fig. 2a, b and Extended Data Fig. 5h-j) . Consequently, inhibition of cyclin D3-CDK6 did not significantly reduce NADPH (Extended Data  Fig. 5k , l) and GSH levels (Extended Data Fig. 5m, n) , and resulted in only a modest increase in ROS levels (Extended Data Fig. 5o, p) . Consistent with these findings, cells expressing both phosphomimicking PFKP and PKM2 mutants were largely protected against apoptosis triggered by inhibition of cyclin D3-CDK6, but not against apoptosis caused by other stimuli (Fig. 2g, h and Extended Data Fig. 5q-x) . Importantly, these cells-like their wild-type counterparts-underwent cell cycle arrest upon palbociclib treatment (Extended Data Fig. 5y, z) .
We also engineered human T-ALL cells to inducibly express, in place of wild-type PFKP and PKM2, mutant versions of these enzymes containing phospho-inactivating substitutions in cyclin D3-CDK6-dependent phosphoresidues (Extended Data Fig. 6j ). Simultaneous induction of phospho-inactivating PFKP and PKM2 mutants resulted in a decrease in NADPH and GSH levels (Extended Data Fig. 6k, l) and an increase in ROS levels (Extended Data Fig. 6m) , and triggered tumour cell apoptosis (Extended Data Fig. 6n ).
To verify these findings in vivo, we intravenously injected human T-ALL cells expressing either wild-type PFKP and PKM2 or phosphomimicking PFKP and PKM2 mutants into immunocompromised mice. When the recipient mice developed disseminated leukaemia, we treated them with palbociclib. As reported before 7 , treatment with palbociclib resulted in apoptosis of human leukaemic cells in vivo. In contrast, T-ALL cells expressing phosphomimicking PFKP and PKM2 mutants were essentially protected against palbociclib-induced apoptosis (Fig. 2i, j) .
These findings are consistent with a model in which cyclin D3-CDK6 phosphorylates and inhibits rate-limiting glycolytic enzymes in leukaemic cells, thereby shunting glucose-derived carbon into the PPP and serine pathways (Fig. 3) . Through this mechanism, cyclin D3-CDK6 promotes the production of NADPH and glutathione and helps to neutralize ROS. Inhibition of cyclin D3-CDK6 in tumour cells decreases the phosphorylation of PFKP and PKM2, resulting in increased activity of these enzymes (Fig. 3) . This diverts carbon away from NADPH and GSH production and decreases NADPH and GSH levels, which in turn results in an increase in ROS and triggers ROSdependent apoptosis. Consistent with this, chemical inhibition of the PPP and/or inhibition of the serine pathway in T-ALL cells essentially phenocopied palbociclib treatment; that is, it decreased NADPH and GSH levels, increased ROS and caused apoptosis (Extended Data Fig. 7) .
In contrast to T-ALL cells, inhibition of CDK4 and CDK6 in breast cancer cells causes cell cycle arrest (and in some cases senescence), but no apoptosis 4,6,7
. We confirmed the absence of significant palbociclib-induced cell death in ten human breast cancer cell lines (Extended Data Fig. 8a ). We established that these cells do not express appreciable levels of CDK6, but instead contain CDK4 along with cyclin D1 (Extended Data Fig. 8b ). Consistent with our observations that cyclin D1-CDK4 complexes do not efficiently phosphorylate PKM2 and PFKP (Extended Data Fig. 2a) , treatment of breast cancer cells with palbociclib failed to reduce the phosphorylation of endogenous PFKP and PKM2 and did not increase the sizes of PFKP and PKM2 complexes (Extended Data Fig. 8c-f ) . Consequently, the enzymatic activity of PFKP and PKM2 in breast cancer cells remained unchanged upon palbociclib treatment (Extended Data Fig. 8g, h ). Inhibition of CDK4/6 did not reduce Cyclin D3-CDK6 phosphorylates and inhibits rate-limiting glycolytic enzymes in tumour cells, thereby shunting glucose-derived carbon into the PPP and serine pathways. Through this mechanism, cyclin D3-CDK6 promotes the production of NADPH and glutathione (GSH) and helps to neutralize ROS. Inhibition of cyclin D3-CDK6 in tumour cells decreases the phosphorylation of PFKP and PKM2, resulting in increased activity of these enzymes. This diverts carbon away from NADPH and GSH production and decreases NADPH and GSH levels, which in turn results in an increase in ROS levels and triggers ROS-dependent apoptosis.
NADPH and GSH levels (Extended Data Fig. 8i , j) and resulted in only a modest increase in ROS (Extended Data Fig. 8k, l) . Importantly, inhibition of PPP and/or inhibition of the serine pathway in breast cancer cells resulted in decreases in NADPH and GSH and an increase in ROS and triggered apoptosis, as seen upon cyclin D3-CDK6 inhibition in T-ALL cells (Extended Data Fig. 8m-o) . Given that there was some increase in ROS levels upon treatment of breast cancer cells with palbociclib, we investigated whether a combination of palbociclib with low levels of PPP inhibitors might have a synergistic effect. Indeed, treatment of breast cancer cells with palbociclib plus low doses of a PPP inhibitor 6-aminonicotinamide (6-AN) synergistically increased ROS levels and caused apoptosis of breast cancer cells (Extended Data Fig. 8p, q) . Hence, combined administration of palbociclib and PPP inhibitors might phenocopy cyclin D3-CDK6 inhibition in T-ALL cells, and result in killing of breast cancer cells.
Our analyses of T-ALL cells suggested that predominant expression of cyclin D3-CDK6 rendered leukaemic cells susceptible to cell death upon palbociclib treatment. We investigated whether other tumour types that express mainly cyclin D3 and CDK6 would also respond to CDK6 inhibition by undergoing apoptosis. We selected the 20 nonhaematopoietic cell lines with the highest levels of CDK6 and cyclin D3 transcripts out of 1,050 human cancer cell lines in the Cancer Cell Line Encyclopedia (CCLE) (Extended Data Fig. 9a ). We verified that 18 of the 20 selected cell lines expressed high levels of the two proteins (Extended Data Fig. 9b ). Treatment of these 'D3/CDK6-high' tumour cell lines with palbociclib caused apoptosis in 16 of the 18 cell lines; depletion of cyclin D3 or CDK6 had a similar effect (Extended Data Fig. 9c-e) . By contrast, two cell lines in which we failed to confirm high levels of CDK6 or cyclin D3 did not undergo apoptosis upon palbociclib treatment (Extended Data Fig. 9b , f). We also tested 10 cell lines representing different human tumour types with expression levels of CDK6 within the bottom 20% of all cell lines in the CCLE (D3/ CDK6-low cell lines) and found that none of them underwent apoptosis upon palbociclib treatment (Extended Data Fig. 9a , g, h).
Palbociclib treatment or depletion of CDK6 in D3/CDK6-high cell lines decreased phosphorylation of endogenous PFKP and PKM2 (Fig. 4a, b and Extended Data Fig. 9i-k) , leading to an increase in PFKP and PKM2 enzymatic activity (Fig. 4c, d ). This resulted in decreased NADPH and GSH (Fig. 4e , f) and increased ROS (Fig. 4g) , and triggered tumour cell death ( Fig. 4h and Extended Data Fig. 9c ). By contrast, treatment of D3/CDK6-low tumour cell lines with palbociclib had no major effect on these parameters (Extended Data Fig. 9l-n) .
To directly link altered phosphorylation of PFKP and PKM2 in D3/CDK6-high cell lines upon palbociclib treatment to tumour cell death, we engineered two D3/CDK6-high tumour cell lines to express-in place of wild-type PFKP and PKM2-PFKP and PKM2 mutants containing phosphomimicking substitutions within cyclin D3-CDK6-dependent residues. These cells were essentially protected against palbociclib-induced apoptosis ( Fig. 4h and Extended Data Fig. 9o-r) . We concluded that in D3/CDK6-high cells, cyclin D3-CDK6 kinase promotes tumour cell survival by phosphorylating PFKP and PKM2.
We obtained 33 primary, patient-derived melanomas, grafted them into immunocompromised mice, and treated tumour-bearing mice with another inhibitor of CDK4 and CDK6, ribociclib 2 . As expected, most of tumours responded to inhibition of CDK4/6 by reducing their growth rate (Extended Data Fig. 10a, b) . By contrast, three tumours underwent long-term regression upon ribociclib treatment (Extended Data Fig. 10c-e) . Analysis of CDK6 and cyclin D3 levels in the primary tumours (before they were grafted into mice) revealed that all three melanomas that underwent long-term regression expressed high levels of CDK6 and cyclin D3 and of cyclin D3-CDK6 complexes, Relative PKM2 phosphorylation
Phos-S37 PKM2 *** *** ** comparable to the levels seen in T-ALL cells (Extended Data Fig. 10f, g ). By contrast, non-regressing tumours expressed overall low levels of CDK6 and/or cyclin D3 (Extended Data Fig. 10f-h ).
Administration of ribociclib to tumour-bearing animals decreased phosphorylation of endogenous PFKP and PKM2 in D3/CDK6-high tumours in vivo (Fig. 5a , b and Extended Data Fig. 10i ), resulting in increased enzymatic activity of PFKP and PKM2 (Fig. 5c, d ), decreased levels of GSH (Fig. 5e ) and increased ROS levels in tumours (Fig. 5f ). By contrast, none of these parameters was affected by inhibition of CDK4/6 in cyclin D3/CDK6-low tumours (Fig. 5a-f and Extended Data Fig. 10j ). These observations indicate that cyclin D3-CDK6 also plays a pro-survival function in D3/CDK6-high melanomas.
Collectively, these observations suggest that human cancers that express high levels of cyclin D3 and CDK6 respond to inhibition of CDK4/6 by undergoing tumour cell death, whereas cancers that predominantly express other types of cyclin D-CDK4/6 complexes undergo cell cycle arrest. Hence, analysis of cyclin D3-CDK6 levels in primary tumours might allow us to identify cancers that are particularly amenable to anti-CDK4/6 therapy, as they would undergo tumour cell death upon inhibition of CDK4 and CDK6.
The work described here shows that in human tumours with high levels of cyclin D3-CDK6, this kinase serves as a rate-limiting regulator of carbon flow into the PPP and serine pathways, in addition to the well-established roles of cyclin D-CDK4/6 kinases in driving cell cycle progression through phosphorylation of RB1. Hence, cyclin D3-CDK6, by its ability to link cell cycle and metabolism, represents a particularly powerful oncogenic kinase that influences cancer cell biology at several levels. This multifaceted role of cyclin D3-CDK6 makes it an appealing target for cancer therapy, as its inhibition affects both cell proliferation and cell metabolism and triggers tumour cell apoptosis. Given the wide use of inhibitors of CDK4 and CDK6 in clinical trials and the great promise they hold, these studies have the potential to improve the clinical efficacy of anti-CDK4/6 therapy.
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Phosphofructokinase activity assays. The activity of phosphofructokinase was measured using Phosphofructokinase Activity Colorimetric Assay Kit (Bio Vision, catalogue #K776-100). We lysed 2 × 10 6 cells in 100 μ l of PFK Assay Buffer (Bio Vision) and used 10 μ l lysate per assay. For patient-derived xenograft tumour samples, 20 mg of tumour was homogenized in 200 μ l PFK Assay Buffer and 50-200 μ g of tumour lysate was used. Absorbance was measured at 450 nm for at least two time points. The activity of PFK1 was calculated by dividing the amount of generated NADH by the reaction time and was normalized against protein concentration. For analyses of purified, recombinant PFKP (Extended Data Fig. 3a) , PFK1 activity was determined by the coupled assay method [21] [22] [23] . In this assay, 2 μ g wild-type or mutant PFKP protein was added to the phosphofructokinase reaction mixture: 95 mM Tris-HCl pH 8.2, 100 mM MgCl 2 , 2 mM NADH (Sigma), 100 mM NH 4 Cl, 20 mM fructose-6-phosphate (Sigma) and 1 mM AMP in the presence of 70 mg/l aldolase (Sigma), 3 mg/l phosphotriose isomerase (Sigma), and 30 mg/l glycerol-3-phosphate dehydrogenase (Roche). PFK1 activity was measured by monitoring the decrease in absorbance at 340 nm (at room temperature) using a microplate spectrophotometer (Benchmark Plus TM , Bio-Rad). In Extended Data  Fig. 3a , the lower panel shows a Coomassie-stained gel of proteins used for the assay. The indicated amounts of bovine serum albumin (BSA) were resolved on the same gel, to allow protein quantification. Pyruvate kinase activity assays. Pyruvate kinase enzymatic activity was measured using Pyruvate Kinase Activity Colorimetric/Fluorometric Assay Kit (Bio Vision, catalogue #K709-100). We lysed 1 × 10 6 cells in 200 μ l Assay Buffer and used 50 μ l per assay. For patient-derived xenograft tumour samples, 20 mg of tumour was homogenized in 200 μ l PKM Assay Buffer and 50-200 μ g of tumour lysate was used. For analyses of purified, recombinant PKM2 (Extended Data Fig. 3b ), 2 μ g wild-type or mutant PKM2 protein with or without phosphorylation by cyclin D3-CDK6 was added to the reaction mix. The fluorescence was measured at excitation/emission = 535/587 nm twice: T1, immediately after cell lysate or protein was added; and T2, after 20 min of incubation. A pyruvate standard curve was used to quantify the amount of pyruvate. Pyruvate kinase activity was calculated by dividing the amount of pyruvate generated between T1 and T2 (T2− T1) by the time. In Extended Data Fig. 3b , the first panel below the graphs shows a Coomassiestained gel of proteins used for the assay. The indicated amounts of BSA were resolved on the same gel, to allow protein quantification. For the panel below, proteins were immunoblotted with an antibody detecting serine 37-phosphorylated PKM2 (Phos-S37-PKM2). The lowest panel shows immunoblotting with an anti-PKM2 antibody. In assays using cell lysates, activity was normalized against protein concentration. MANT-ADP binding assay. 2′ /3′ -O-(N-methylanthraniloyl)-ADP (MANT-ADP, LifeTech) was used to measure nucleotide binding as described 24, 25 . In this assay, the fluorescent moiety is attached to the ribose, leaving the purine ring and phosphate groups free for binding. Recombinant wild-type or mutant glutathione-S transferase (GST)-PFKP (2.5 μ g (22.3 pmol)) was bound to glutathione beads, and the beads were washed with PFK1 Assay Buffer (Bio Vision) plus 2% glycerol. Different amounts of MANT-ADP (10 nM, 100 nM, 1 μ M, 10 μ M or 100 μ M; Extended Data Fig. 3g ) in 100 μ l PFK1 Assay Buffer were added to the beads and incubated at room temperature for 10 min. The beads were then washed with 1 ml ice-cold PFK1 Assay Buffer containing the same concentration of non-fluorescent ADP, resuspended in 100 μ l of the PFK1 Assay Buffer, and the fluorescence (excitation/emission = 380/429 nm) was measured using a plate reader (Fluostar OPTIMA, BMG LABTECH). A standard curve of MANT-ADP was used to quantify the amount of ADP bound by the proteins. 'Empty' GST beads incubated with MANT-ADP were used as a negative control. The binding affinity of wild-type and mutant PFKP proteins to ADP, with or without preincubation with cyclin D3-CDK6 kinase (Extended Data Fig. 3e ), was measured in the presence of 100 μ M MANT-ADP. In Extended Data Fig. 3f , different amounts (35.6, 71.1 or 142.2 pmol) of wild-type or mutant PFKP proteins were tested in the presence of 100 μ M MANT-ADP. In Extended Data Fig. 3g , the lower panel shows a Coomassie-stained gel of proteins used for the assay, along with the indicated amounts of BSA. Native gels for separation of PFKP or PKM2 dimers and tetramers. Flag-tagged wild-type PFKP or PFKP mutants were expressed in MCF7 cells (Extended Data Fig. 3h ) and Flag-tagged wild-type PKM2 or PKM2-S37E mutant were expressed in EBC1 and HUCCT1 cells (Extended Data Fig. 3n ). The NativePAGE TM Novex Bis-Tris gel system (Life Technologies) was used to separate PFKP or PKM2 dimers and tetramers. Cells were lysed in 1× NativePAGE TM sample buffer supplemented with 1% digitonin and protease inhibitors. The samples were homogenized, incubated on ice for 10 min, and then centrifuged at 16,100g for 30 min at 4 °C. The supernatants were mixed with NativePAGE sample buffer and NativePAGE 5% G-250 Sample Additive and applied to a NativePAGE gel. Proteins were transferred to PVDF membranes (Merck Millipore); membranes were then incubated with 8% acetic acid for 15 min, followed by immunoblotting with an anti-Flag antibody to detect PFKP tetramers (molecular mass 342 kDa) and dimers (171 kDa), or PKM2 tetramers (232 kDa) and dimers (116 kDa). Fig. 3j , k, 3× Flag-tagged PFKP-WT, PFKP-S679A or PFKP-S679E were stably expressed in MOLT4 cells; 1 × 10 7 cells were collected and lysed in immunoprecipitation lysis buffer (Pierce) with protease and phosphatase inhibitors. Whole-cell lysates were then filtered using Disposable Ultrafiltration Units with a cutoff of molecular mass 200 kDa (USY-20, Advantec MFS). The molecular mass of PFKP dimers (171 kDa) or PKM2 dimers (116 kDa) is below this cutoff, and hence the dimers can pass through the filter. By contrast, the molecular mass of PFKP tetramers (342 kDa) or PKM2 tetramers (232 kDa) does not allow passage through the filter. Ten micrograms of each filtrate (< 200 kDa fraction) was collected, denatured, resolved on PAGE along with 20 μ g of the original whole-cell lysates (before filtration) and immunoblotted with the indicated antibodies. Immunoblotting for LRP6 (molecular mass 180 kDa, expected to pass the filter) and for BRCA1 (208 kDa, not passing the filter) were used to verify the success of the ultrafiltration. In experiments shown in Extended Data Figs 3l, m, 5f , g, 8e, f, whole-cell lysates were prepared from KOPTK1, MOLT4, KOPTK1-EE and MOLT4-EE T-ALL cells or MCF7, HCC1428 and BT474 breast cancer cells cultured in the presence of 1 μ M palbociclib for 24 h (or cultured without palbociclib), filtered and analysed as above. NADPH quantification. Intracellular NADPH was measured using a NADP/ NADPH Quantification Colorimetric Kit (BioVision). In vitro cultured cells (4 × 10 5 for leukaemic cells, 2 × 10 5 for adherent cells) were collected and lysed. The samples were heated to 60 °C for 30 min, NADP cycling enzyme mix and NADPH developer were added, and absorbance was measured at 450 nm using microplate spectrophotometer (Benchmark PLUS TM , Bio-Rad). NADPH was quantified by comparing with an NADPH standard curve; NADPH levels were normalized against protein concentration. GSH measurements. Intracellular GSH was quantified using a Glutathione Fluorometric Assay Kit (Biovision). Cells (4 × 10 6 ) were collected, lysed in glutathione assay buffer and mixed with pre-chilled perchloric acid. For patientderived xenograft tumour samples, 40 mg of tumour was homogenized in 100 μ l ice-cold glutathione assay buffer and mixed with pre-chilled perchloric acid. Supernatants were collected, OPA (o-phthalaldehyde) probe was added, the samples were incubated at room temperature for 40 min and fluorescence was measured at excitation/emission = 340/420 nm (Fluostar OPTIMA, BMG LABTECH). GSH was quantified by comparing with a GSH standard curve; GSH levels were normalized against protein concentration. Intracellular ROS detection. The amount of intracellular ROS was measured by detecting dichlorodihydrofluorescein, the cleavage product of carboxy-H2DCFDA (2′ ,7′ -dichlorodihydrofluorescein diacetate) by ROS. In vitro cultured cells were washed with PBS and loaded with 5 μ M carboxy-H2DCFDA (Invitrogen) for 30 min. Cells were then removed, resuspended in phenol red-free medium and cultured for additional 30 min (for suspension cells). For adherent cells, cells were dissociated with accutase after 30 min culture in phenol red-free medium. The fluorescent signals from cells were analysed by FACS (BD LSR Fortessa; excitation/emission = 488/530 nm) or analysed by plate reader (Fluostar OPTIMA, BMG LABTECH) (Fig. 2e and Extended Data Fig. 4i ). In Extended Data  Fig. 8l , the absolute ROS levels were normalized against protein concentration, to account for the difference in cell size between T-ALL and breast cancer cells. ROS and reactive nitrogen species (RNS) measurement in patient-derived xenograft tumour tissue. OxiSelectTM In vitro ROS/RNS assay kit (green fluorescence) (Cell Biolabs, cat. STA-347) was used to measure ROS and RNS in xenograft tumours. Twenty milligrams of tumour tissue was homogenized in 1 ml ice-cold PBS. The homogenized samples were centrifuged at 10,000g for 5 min to remove insoluble particles. Fifty microlitres of supernatant was mixed with 50 μ l catalyst (provided in the kit) to accelerate the oxidative reaction. Following 5 min incubation at room temperature, 100 μ l DCFH-DiOxyQ probe solution was added to the mixture to measure the total free radical population. The DCFH probe can react with free radical molecules that are representative of both ROS and RNS. The samples were incubated at room temperature for 30 min and read with a fluorescence plate reader at excitation/emission = 480/530 nm. The standard curve of H 2 O 2 was used to quantify the free radical content in the tumour lysate samples. 
200-kDa cutoff ultrafiltration. In experiments shown in Extended Data
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Extraction of intracellular metabolites. Cells were collected, washed in 0.9% NaCl and lysed in 500 μ l acetonitrile/methanol/H 2 O (40/40/20) at − 20 °C. Cell lysates were centrifuged at 13,200 r.p.m. for 15 min and supernatants were then lyophilized and stored at − 80 °C. Derivatization. Samples were extracted in 80% methanol and 20% water and frozen on dry ice. Flash-thawed samples were lyophilized, and then dissolved in 30 μ l 2% methoxyamine hydrochloride in pyridine (MOX) (Thermo TS-45950) at 37 °C for 1.5 h. Samples were then derivatized by adding 45 μ l N-methyl-N-( tertbutyldimethylsilyl) trifluoroacetamide (MBTSTFA) + 1% tert-butyldimethylchlorosilane (TBDMCS) (Sigma 375934) at 60 °C for 1 h. Gas chromatography mass spectrometry analysis was performed as previously described 26 . Cell apoptosis assays. Cell apoptosis was quantified either using Caspase-Glo3/7 Assay (Promega) or Annexin V Apoptosis Detection Kit (eBioscience). For Caspase-Glo3/7 Assay, medium containing 1 × 10 4 cells was mixed with an equal volume of Caspase-Glo reagent and incubated for 1 h, and the luminescence was measured using a microplate luminometer (Veritas TM , Turner BioSystems). For annexin V staining, 2 × 10 6 cells were collected and suspended in binding buffer (eBioscience). For adherent cells, accutase (Millipore) was used to detach cells from the plates. Cells were stained with fluorochrome-conjugated annexin and with propidium iodide and analysed by flow cytometry (BD LSR Fortessa). Cell cycle analyses. Cells were incubated in medium containing 75 μ M 5-bromo-2′ -deoxyuridine (BrdU) for 1 h, collected and fixed overnight in 90% ethanol. Cells were then treated with 2 N HCl containing 0.5% Triton X-100, neutralized in borate buffer pH 8.5, incubated with an anti-BrdU antibody (556028, BD Biosciences), 5 μ g/ml propidium iodide and 200 μ g/ml RNase A for 30 min, and analysed by FACS. Plasmid construction. PFKP in p3×FLAG-CMV-10 or in pBABE-hygro. DNA sequence encoding human PFKP was PCR-amplified from plasmid pDONR 223-PFKP (# 23869, Addgene), using primers 5′-GGGGAATTCCAT GGACGCGGAC-3′ and 5′-GGGGATATCAGACACTCCAGGGCTGCACAT-3′ and cloned into the EcoRI and EcoRV sites of p3× Flag-CMV-10 expression vector (N-terminal). Primers 5′-CAGGGTGGGGCACCCGCTCCATTTGATAGAAA-3′ and 5′-GCAGCAGGGTGGGGCACCCGAGCCATTTGATAGAAACTTTGG-3′ were used to amplify the S679A and S679E mutants of PFKP, respectively, using Quikchange II XL site-directed Mutagenesis kit (Agilent Technologies). DNA sequences encoding wild-type or mutant PFKP were also PCR-amplified from p3× FLAG-CMV-10 using primers 5′-GGGGGATCCATGGACTACAAA GACCATGAC-3′ and 5′-GGGTACGTATCAGACACTCCAGGGCTGCA-3′ , and subcloned into the BamHI and SnaBI sites of pBABE-hygro retrovirus. PFKP/PFKM/PFKL in pGEX-5T-3. DNA sequence encoding human PFKP was PCR-amplified from plasmid pDONR 223-PFKP (# 23869, Addgene), using primers 5′-GGGGAATTCCATGGACGCGGACGACTC-3′ and 5′-GGGGCGGCCGCCGACACTCCAGGGCTGCAC-3′ , and cloned into the EcoRI and NotI sites of pGEX-5T-3. DNA sequence encoding human PFKM was PCR-amplified from plasmid pWZL Neo Myr Flag PFKM (# 20568, Addgene), using primers 5′-GGGGGATCCCCATGACCCATGAAGAGCACCA-3′ and 5′-GGG GCGGCCGCCCTAGACGGCAGCTTCCCCGG-3′ , and cloned into the BamHI and EcoRI sites of pGEX-5T-3. DNA sequence encoding human PFKL was PCR-amplified from plasmid pWZL Neo Myr Flag PFKL (# 20657, Addgene) using primers 5′-GGGGAATTCCATGGCCGCGGTGGACC-3′ and 5′-GGGGCGGCCGCCTTAGAAGCCCTTGTCCATGCTCA-3′ , and cloned into the EcoRI and NotI sites of pGEX-5T-3. PKM2 in pWZL retroviral vector. DNA sequence encoding human PKM2 in pWZL retrovirus vector was purchased from Addgene (#20585). S37A and S37E mutants of PKM2 were obtained with primers 5′-TGTGCCGCCTGG ACATTGATGCACCACCCATC-3′ and 5′-CATGTGCCGCCTGGACATTGA TGAGCCACCCATCACAGCC-3′ using a Quikchange II XL site-directed Mutagenesis kit (Agilent Technologies). PKM2 in pMSCV-Neo. DNA sequence encoding human PKM2 (or S37E mutant) was PCR-amplified from plasmid PKM2 (or S37E mutant) in pWZL retroviral vector, using primers 5′-CCGAGGAATTCATGTCGAAGCCCCATAGTG-3′ and 5′ -AATACCTCGAGTCACGGCACAGGAACAACA-3′. The PCR product was then cloned into pMSCV-neo plasmid at the EcoRI and XhoI sites.
PFKP-P2A-PKM2 (or S679A-P2A-S37A mutant) in p40 inducible vector. DNA sequence encoding human PFKP (or S679A mutant) was PCR-amplified from plasmid PFKP (or S679A mutant) in p3XFLAG-CMV-10, using primers 5′-CGTCGCGCTAGCATGGACTACAAAGACCATGACGGTG-3′ and 5 ′-A CG TC GC CG GC CT GC TT CA GC AG GG AG AA GT TG GT GG CG CC GA CAC TCCAGGGCTGCACA-3′; DNA sequence encoding human PKM2 (or S37A mutant) was PCR-amplified from plasmid PKM2 (or S37A mutant) in pWZL retroviral v ec to r, using primers 5′-T GC TG AA GC AG GC CG GC GA CG TG GA GG AG AA CC CC GG CC CC AT GTCGAAGCCCCATAGTG-3′ and 5′-G CG TT AA TT AA TC AC GG CA CA GG AA CA AC AC GC AT GGTGTTGGTGAAGCC-3′. The C-terminal part of the PCR-amplified sequence encoding PFKP was flanked by a part of the P2A sequence (self-cleaving P2A peptide sequence), and the N-terminal part of the PCR-amplified sequence encoding PKM2 was flanked by another part of the P2A sequence. The PFKP and PKM2 PCR products were then annealed at the P2A sequence through NEBuilder reaction (NEBuilder HiFi DNA Assembly Cloning Kit, cat. E5520S, New England Biolabs). The DNA sequence encoding PFKP-P2A-PKM2 was PCR-amplified from the first-round annealed PCR product using primers 5′ -CGTCGCGCTAGCATGGACTACAAAGACCATGACGGTG-3′ and 5′ -GCGTTAATTAATCACGGCACAGGAACAACACGCATGG TGTTGGTGAAGCC-3′ . The amplified PFKP-P2A-PKM2 sequence was then cloned into a p40 inducible vector at the NheI and PacI restriction sites. 3×FLAG-PKM2 (or S37E mutant) in pDEST_FUGW_ires PURO. DNA sequence encoding human PKM2 (or S37E mutant) was PCR-amplified from plasmid PKM2 (or S37E mutant) in pWZL retroviral vector, using primers 5′-GGGGA CAAGTTTGTACAAAAAAGCAGGCTATATGTCGAAGCCCCATAGTGAAGC CG-3′ and 5′-G GG GA CC AC TT TG TA CA AG AA AG CT GG GT CT CA CG GCA CAGGAACAACAC-3′. cDNA sequences were introduced into the destination lentiviral FUGW vector using the GATEWAY cloning protocol. shRNA constructs. shRBL2 in pLKO.1-neo vector. DNA oligomers 5 ′-C CG GT CC GG GA CT AG GA GA CA TG GA TT TA TC TC GA GA TA AA TC CATGTCTCCTAGT CTTTTTG-3′ and 5 ′-A AT TC AA AA AG AC TA GG AG AC AT GG AT TT AT CT CG AG AT AA AT CC ATGTCTCCTAGTCCCGGA-3′ were annealed and cloned into pLKO.1 neo plasmid (cat. 13425, Addgene) at the EcoRI and AgeI sites. shPKM2 in pLKO.1-neo vector. DNA oligomers 5′-C CG GT CC GG CA AC GC TT GT AG AA CT CA CT CC TC GA GG AG TG AG TT CTACAAGCGTTGTTTTTG-3′ and 5′-AATTCAAAAACAACGCTTGTAGAACTCACTCCTCGAGGAGTGAGTTC TACAAGCGTTGCCGGA-3′ were annealed and cloned into a pLKO.1 neo plasmid at the EcoRI and AgeI sites. shRBL1 in pGFP-B-RS. DNA oligomers 5′-GATCCCCGGCATCGA TAGTGATGCAGAATCCTCGAGGATTCTGCATCACTATCGATGTTTTTGA -3′ and 5′-AGCTTCAAAAACATCGATAGTGATGCAGAATCCTCGA GGATTCTGCATCACTATCGATGCCGGG-3′ were annealed and cloned into a pGFP-B-RS plasmid (cat. TR30018, Origene) at the BamHI and HindIII sites. shCDK6 in pGFP-B-RS. DNA oligomers 5′-GATCCCCGGTCTGGAGT GTTGGCTGCATATCTCGAGATATGCAGCCAACACTCCAGATTTTTA-3′ and 5′-AGCTTAAAAATCTGGAGTGTTGGCTGCATATCTCGAGATATGCAGCC AACACTCCAGACCGGG-3′ were annealed and cloned into a pGFP-B-RS plasmid at the BamHI and HindIII sites. shPFKP in pGFP-B-RS. DNA oligomers 5′-GATCCCCGGCAGCACT TTATGCACGTATTACTCGAGTAATACGTGCATAAAGTGCTGTTTTTTGA -3′ and 5′-AGCTTCAAAAAACAGCACTTTATGCACGTATTACTCGAG TAATACGTGCATAAAGTGCTGCCGGG-3′ were annealed and cloned into a pGFP-B-RS plasmid at the BamHI and HindIII sites. Viral transduction and transfection. Retroviral and lentiviral plasmids were packaged in HEK293T cells by co-transfecting expression plasmids together with the packaging plasmid (pCMV-Gag-Pol for retroviral infections, pCMV-delta8.9 for lentiviral infections) and the envelope plasmid (pCMV-VSV-G), using Lipofectamine 2000 transfection reagent (using a plasmid ratio of pCMV-VSV-G/pCMV-Gag-Pol/expression plasmid 3/5/10 for retroviral transductions, and a ratio of pCMV-VSV-G/pCMV-delta8.9 /expression plasmid 1/5/10 for lentiviral transductions). Virus-containing medium was collected two days after transfection, filtered and used for infection in the presence of 10 μ g/ml polybrene. After 24 h, virus-containing medium was replaced by fresh medium, and cells were selected for 2 weeks with puromycin (2 μ g/ml), neomycin (400-1,000 μ g/ml) or hygromycin (200 μ g/ml). shRNAs against PFKP (3′ untranslated region (UTR), TRCN0000195199, 5′-CCGGCA GCACTTTATGCACGTATTACTCGAGTAATACGTGCATAAAGTGCTGTTTT TG-3′ ), PKM2 (3′ UTR, TRCN0000296768, 5′-CCGGCAACGCTTGTAGAA CTCACTCCTCGAGGAGTGAGTTCTACAAGCGTTGTTTTTG-3′ ) and cyclin D3 (3′ UTR, TRCN0000338380, 5′-CCGGCTAGGGTTATTGCATTTGGAT-CT CGAGATCCAAATGCAATAACCCTAG-TTTTTG-3′ ) in pLKO.1-puro vector were obtained from the RNAi Consortium (https://www. broadinstitute. org/rnai/trc). shRNA against PSAT1 (TRCN0000291729, 5′-CCGGGCA Letter reSeArCH CTCAGTGTTGTTAGAGATCTCGAGATCTCTAACAACACTGAGTGCTTTT TG-3′ ) in pLKO.1-puro vector was obtained from Sigma. shRNAs against RB1 (pMKO.1 puro Rb shRNA) and CDK6 (pSIREN-RetroQ-CDK6-shRNA) were obtained from Addgene. PKM2-expressing vector (pWZL Neo Myr Flag PKM2) was also obtained from Addgene. Other shRNAs were constructed as indicated in plasmid construction. CMV-cyclin D3 and CMV-CDK6 (wild type or kinase-dead K43M mutant) were transiently co-transfected into MCF7 cells using Lipofectamine 2000 (Invitrogen), and the activity of endogenous PFK1 or PKM2 was measured 3 days after transfection. shRNAs against CDK6 or cyclin D3 were transduced into DND41, KOPTK1, MOLT4, KOPTK1-WT, KOPTK1-EE, MOLT4-WT, MOLT4-EE, EBC1 and HUCCT1 cells. The knockdown efficiency of CDK6 and cyclin D3, cellular NADPH, GSH or ROS levels, phosphorylation levels and the enzymatic activity of PFKP and PKM2 were measured after 2 days of puromycin selection. Cell apoptosis was measured after 3 days of puromycin selection. Generation of KOPTK1, MOLT4, EBC1 or HUCCT1 cells stably expressing wild-type or mutant PFKP or PKM2. To generate KOPTK1-WT, KOPTK1-EE, MOLT4-WT or MOLT4-EE cells, KOPTK1 or MOLT4 cells were transduced with pLKO.1-puro vector encoding shRNA targeting the 3′ UTR of PKM2, and then transduced with pLKO.1-puro vector encoding shRNA targeting the 3′ UTR of PFKP (selection in 2 μ g/ml puromycin). The efficiency of knockdown was verified by immunoblotting with anti-PKM2 and anti-PFKP antibodies. Subsequently, cells were transduced with pMSCV-Neo PKM2 expressing wild-type PKM2 or the S37E mutant, selected with neomycin (400 μ g/ml), transduced with pBABE-hygro vector expressing 3× Flag-tagged wild-type or S679E mutant PFKP, and selected with hygromycin (100 μ g/ml). The levels of ectopically expressed proteins were then verified by immunoblotting. To generate EBC1-WT, EBC1-EE, HUCCT1-WT or HUCCT1-EE cells, EBC1 or HUCCT1 cells were transduced with pLKO.1-neo vector encoding shRNA targeting the 3′ UTR of PKM2 (selection in 1,000 μ g/ml neomycin), and then transduced with pGFP-B-RS vector encoding shRNA targeting the 3′ UTR of PFKP (blasticidin selection: 5 μ g/ml for EBC1 and 20 μ g/ml for HUCCT1). Subsequently, cells were transduced with pDEST_FUGW_iresPURO PKM2 encoding 3× Flag-tagged wild-type or S37E mutant PKM2, selected with puromycin (2 μ g/ml), transduced with pBABE-hygro vector encoding 3× Flagtagged wild-type or S679E mutant PFKP, and selected with hygromycin (200 μ g/ml). To generate single mutant PFKP-S679E and control PFKP-WT cells, KOPTK1, MOLT4, EBC1 or HUCCT1 cells were transduced with pGFP-B-RS vector encoding shRNA targeting the 3′ UTR of PFKP, and selected with blasticidin; subsequently, cells were transduced with pBABE-hygro vector encoding 3× Flag-tagged wild-type or S679E mutant PFKP, and selected with hygromycin. To generate single mutant PKM2-S37E and control PKM2-WT cells, KOPTK1, MOLT4, EBC1 or HUCCT1 cells were transduced with pLKO.1-neo vector encoding shRNA targeting the 3′ UTR of PKM2, and selected with neomycin; subsequently, cells were transduced with pDEST_FUGW_iresPURO PKM2 encoding 3× Flag-tagged wild-type or S37E mutant PKM2 and selected with puromycin. To generate doxycycline-inducible MOLT4-WT and MOLT4-AA cells, MOLT4 cells were transduced with p40 inducible vector simultaneously expressing wild-type PFKP and PKM2 or PFKP-S679A and PKM2-S37A (the two proteins were linked by the P2A sequence), and selected with puromycin. Cells were then transduced with pLKO.1-neo vector encoding shRNA targeting the 3′ UTR of PKM2 (neomycin selection), and were transduced with pGFP-B-RS vector expressing shRNA targeting the 3′ UTR of PFKP (blasticidin selection). For KOPTK1 or MOLT4 cells, 5 μ g/ml blasticidin was used for selection. In Extended Data Figs 5a, 6a, 6j and 9p the shRNAs were directed against the 3′ UTRs of PFKP or PKM2, and hence they do not target ectopically expressed PFKP and PKM2. In Extended Data Fig. 5a , the ectopically expressed wild-type PFKP and PFKP-S679E contain a 3× Flag tag, and hence they show slightly retarded migration on SDS-PAGE gels. In Extended Data Figs 6a and 9p, the ectopically expressed PKM2 and PFKP contain a 3× Flag tag, and hence they show slightly retarded migration on SDS-PAGE gels. Also note that ectopically expressed PFKP and PKM2 proteins (wild-type and mutant) are expressed at physiological levels, corresponding to the levels of endogenous PFKP and PKM2 (Extended Data Figs 5a, 6a, 6j, 9p) . Expression and purification of recombinant GST-PFK1 and His-PKM2. Human PFKP, PFKL and PFKM cDNAs were cloned into a pGEX-5X-3 expression vector, and human PKM2 was cloned into a pET30a vector. A Quikchange Lightning Multi Site-Directed Mutagenesis Kit (Agilent Technologies) was used to generate PFKP mutants S679A and S679E, and PKM2 mutants S37A and S37E. Plasmids were transformed into Escherichia coli BL21 (DE3). Expression of recombinant proteins was induced with 0.1 mM isopropyl β -d-1-thiogalactopyranoside (IPTG) for 6 h at 37 °C. Bacterial pellets were lysed by sonication in PBS pH 7.4 containing 1% N-lauroyl sarcosine, 1 mM EDTA, 10 mM DTT and protease inhibitors. The supernatant was collected by centrifugation and glutathione agarose was used to purify GST-PFK1. Ni-NTA agarose was used to purify His-tagged PKM2. GST-PFK1 was eluted from glutathione agarose using elution buffer: 25 mM glutathione, 200 mM NaCl in 50 mM Tris pH 8.8. Proteins were dialysed and concentrated before being used for kinase reactions or for PFK1 activity measurements. To elute His-PKM2 from Ni-NTA agarose, 200 mM imidazole in TKET buffer (10 mM Tris-HCl pH 7.5, 100 mM KCl, 0.1 mM EDTA, and 0.05% Triton X100) was used. His-PKM2 was then dialysed and used for assays. In vitro kinase assays. Kinase assays were performed in a final volume of 30 μ l kinase buffer: 50 mM HEPES pH 7.5, 10 mM MgCl 2 , 1 mM DTT, 1 mM EGTA, 0.1 mM NaF, containing 10 μ M ATP and 0.4 mCi [ 32 P]γ ATP (Perkin Elmer). Cyclin D1-CDK4 (0.1 μ g; ab55695, Abcam), cyclin D3-CDK4 (0.1 μ g; ab85646, Abcam), cyclin D1-CDK6 (0.1 μ g; C1374, Sigma), or cyclin D3-CDK6 (0.1 μ g; 14-519, Millipore) were used as kinases. One microgram of GST-PFKP, GST-PFKM or GST-PFKL immobilized on glutathione-agarose beads, or His-PKM2 immobilized on Ni-NTA beads, or 2 μ g recombinant PKM1 (cat. 40502), PKL (cat. 40501) or PKR (cat. 40500) obtained from BPS BioScience were used as kinase substrates. GST-RB1 or RB1 C-terminal recombinant protein (cat. SC-4112, Santa Cruz) were used as a positive control for kinase assays. After 30 min incubation at 30 °C, proteins were denatured, resolved on SDS-PAGE, transferred to nitrocellulose membranes and exposed to X-ray films (marked in figures as 32 P). In Extended Data Fig. 2c , bovine serum albumin in place of substrates (− ) was used as a negative control. For endogenous kinase assays (Fig. 1b) , the endogenous CDK6 was immunoprecipitated from KOPTK1 or MOLT4 whole-cell lysates. Recombinant PFKP or PKM2 was used as a substrate in the presence or absence of 1 μ M palbociclib (MedChem Express). Identical results were obtained with T-ALL RPMI8402 cells; these data are not shown owing to the inclusion of RPMI8402 cells in the list of potentially misidentified cell lines. To measure the enzymatic activities of PFKP or PKM2 phosphorylated by cyclin D3-CDK6, the kinase reaction mixtures were incubated for 60 min. Immunoprecipitation, western blotting and recombinant proteins. Cells were lysed in lysis buffer (20 mM Tris-HCl pH 8.0, 0.1 M KCl, 5 mM MgCl 2 , 10% glycerol, 0.1% Tween-20, 0.1% NP40) with protease and phosphatase inhibitors (Roche) for co-immunoprecipitation experiments. For protein immunoprecipitation followed by immunoblotting with anti-phospho-antibodies, immunoprecipitation lysis buffer (Piece) was used. One milligram of protein lysate was used for immunoprecipitation with 30 μ l anti-CDK6 antibody conjugated to Sepharose beads (sc-177AC, Santa Cruz) or with 20 μ l of anti-PKM2 antibody (D78A4, Cell Signaling) conjugated to Sepharose beads. The same amount of normal rabbit IgG-AC (sc-2345, Santa Cruz) was used as a control. For PFKP immunoprecipitation, 10 μ g anti-PFKP antibody (ab186132, Abcam) was used, followed by incubation with Protein A/G PLUS-Agarose (from Santa Cruz). Beads were then collected and the proteins denatured, resolved on SDS-PAGE, transferred to nitrocellulose membranes (GE Healthcare Life Sciences) and probed with the antibodies listed below. For immunoblotting, cells were lysed in immunoprecipitation lysis buffer, resolved on SDS-PAGE and transferred to nitrocellulose membranes. Antibodies against the following proteins were used for immunoblotting: PFKP (5412, Cell Signaling or ab186132, Abcam), PFKM (sc-67028, Santa Cruz), PFKL (ab37583, Abcam), PKM1 (7067s, Cell Signaling), phospho-S37-PKM2 (orb76553, Biorbyt), phosphoserine-proline/phosphothreonine-proline (ab9344, Abcam or 05-368, Millipore), PSAT1 (ab96136, Abcam), cyclin D1 (RB-010-P1, Thermo Scientific), cyclin D2 (K0064-3, MBL Code), cyclin D3 (ab28283, Abcam or sc-182, Santa Cruz), CDK4 (MS-616-P1, Thermo Scientific), CDK6 (B-10, Santa Cruz or 3136, Cell Signaling), RB1 (sc-50, Santa Cruz), RBL1 (sc-318, Santa Cruz), RBL2 (sc-317, Santa Cruz), cleaved PARP (9541, Cell Signaling), Flag (F1804, Sigma), GST (2622, Cell Signaling), tubulin (T9026, Sigma), actin (4967, Cell Signaling), LRP6 (sc-25317, Santa Cruz), BRCA1 (MA1-137, Thermo Fisher or 07-434, Millipore). To quantify endogenous protein levels in T-ALL cells (shown in Extended Data  Fig. 1a, b, m, o) , whole-cell extracts from T-ALL cell lines were resolved on SDS-PAGE with known amounts of recombinant proteins (D-type cyclins, CDK4, CDK6, PFK1 isoforms or PKM2), and immunoblots were probed with the indicated antibodies. The following recombinant proteins were used: cyclin D1-CDK4 kinase (ab55695, Abcam), His-cyclin D2 (MBS204235, MyBiosource), cyclin D3-CDK6 kinase (14-519, Millipore), GST-PFKP, GST-PFKL, GST-PFKM and His-PKM2, purified as above. In analyses of the expression of pyruvate kinase isoforms in human T-ALL cell lines (Extended Data Fig. 1n ), we included human lung cancer A549 and human embryonic kidney 293T cells as controls, which were previously shown to express the PKM2 isoform, as well as adult mouse muscle, which expresses PKM1. To quantify PFKP and PKM2 phosphorylation from immunoblots (Figs 1c, 4a Letter reSeArCH used for immunoprecipitation with 200 μ l agarose-conjugated anti-CDK6 antibody (sc-177AC, Santa Cruz) at 4 °C overnight. For control (mock) immunoprecipitations, the same amount of lysate was incubated with 200 μ l IgG conjugated to agarose beads (sc-2345, Santa Cruz). The beads were collected and washed five times with PBS plus 0.1% Tween-20 and once with PBS. Proteins were eluted from the beads in urea buffer (7 M urea, 20 mM Tris pH 7.5, 100 mM NaCl) and analysed by mass spectrometry. Identification of cyclin D3-CDK6-dependent phosphoresidues on PFK1 and PKM2. In vitro kinase reactions were performed in the final volume of 30 μ l kinase buffer (50 mM HEPES pH 7.5, 10 mM MgCl 2 , 1 mM DTT, 1 mM EGTA, 0.1 mM NaF) in the presence of 10 μ M ATP, 0.1 μ g cyclin D3-CDK6 (14-519, Millipore) and 1 μ g GST-PFKP, GST-PFKM or GST-PFKL immobilized on glutathione-sepharose beads, or His-PKM2 immobilized on Ni-NTA beads. After 30 min incubation at 30 °C, proteins were denatured, resolved on denaturing gels and stained with Coomassie blue. Bands corresponding to PFKP, PFKM, PFKL or PKM2 were excised and analysed by mass spectrometry. Mass spectrometry. PFKP, PFKM, PFKL and PKM2 were digested from SDS-PAGE gels using an in-gel digestion protocol where protein digestion was performed overnight using trypsin in a 50 mM Tris buffer pH 8.8 at 37 °C. Peptides were extracted from the gel using 50% acetonitrile and 1% formic acid, which was dried using a vacuum centrifuge. Samples were then desalted using StageTips and dried by vacuum centrifugation.
For CDK6 interactome analysis, affinity-purified complexes were first precipitated with trichloroacetic acid, washed with cold acetone and resuspended in 8 M urea supplemented with 50 mM Tris pH 8.5. Samples were then diluted with 50 mM Tris pH 8.5 and digested overnight with trypsin. Trypsin digests were acidified, desalted using StageTips and dried by vacuum centrifugation.
For in vitro analysis of phosphorylation sites on PFKP, PFKM, PFKL and PKM2, mass spectrometry was performed using an LTQ-Orbitrap Elite hybrid mass spectrometer (Thermo Fisher). The LTQ-Orbitrap Elite instrument was equipped with a Famos autosampler (LC Packings) and an Accela 600 pump (Thermo Fisher). For CDK6 interactome analysis, samples were analysed using either an Orbitrap Elite or an Orbitrap Fusion Tribrid mass spectrometer, which was equipped with a Proxeon ultra high pressure liquid chromoatograph (LC). Each sample was loaded onto a pulled fused silica microcapillary column (125 μ m, 20 cm bed volume) packed with C 18 reverse-phase resin (100 μ m inner diameter microcapillary column packed first with ~ 0.5 cm of 5 μ m Magic C18 resin followed by 40 cm of 1.8 μ m GP-C18 resin). For the Orbitrap Elite experiments, once loaded, the peptides were separated using the Accela pump across a 70-min linear gradient of 3− 22% buffer B (97% acetonitrile, 0.125% formic acid) with an in-column flow rate of 0.5-1 μ l/min. For the Orbitrap Fusion experiments, once loaded, the peptides were separated using the Proxeon HPLC across a 90-min linear gradient of 15− 30% buffer B (97% acetontrile, 0.125% formic acid) with an in-column flow rate of 0.5 μ l/min. Electrospray ionization was performed using 2.0 kV through a PEEK junction inlet of the microcapillary column.
In each data collection cycle for the Orbitrap Elite, one full MS scan (300-1,500 m/z) was acquired in the Orbitrap (6 × 10 4 resolution setting, automatic gain control (AGC0 target of 1 × 10 6 ) and the top 20 most abundant ions were selected for isolation and fragmentation in the ion-trap by collision-induced dissociation (CID). Ions were selected for isolation when their intensity reached a threshold of 500 counts. CID was performed using a 2 m/z isolation window, an AGC setting of 2 × 10 3 , a maximum ion accumulation time of 150 ms and a wide band activation. Each cycle was performed using dynamic exclusion where peptides were excluded from analysis for 60 s after prior analysis. For the Orbitrap Fusion analysis, each data collection cycle was performed with one full MS scan (300-1,500 m/z) acquired using an AGC setting of 1.2 × 10 5 , a resolution of 1.2 × 10 5 and an ion injection time of 100 ms. From this full scan, the top 20 most abundant ions were selected for isolation and fragmentation by collision-induced dissociation with a 35% collision energy. Each fragmentation event was performed with an AGC setting of 5 × 10 3 and an ion injection time of 50 ms using the ion trap. Each cycle was performed using dynamic exclusion where peptides were excluded from analysis for 60 s after prior analysis.
An in-house suite of software tools was used to convert mass spectrometric data from raw files to mzmxl format. Erroneous peptide ion charge state and monoisotopic m/z were corrected as described 32 . MS/MS spectra assignments were made using the Sequest algorithm 33 using the entire mouse Ensembl database (version 3.6). Sequest searches were performed using a target-decoy strategy 34 with the mouse Uniprot database in correct orientation (forward database) and the same database but with all sequences in reverse orientation (reverse database). The data were searched using a precursor ion tolerance of 20 p.p.m. and a fragment ions tolerance of 0.8 Da with trypsin specificity and allowing two missed cleavages. A dynamic modification on methionine (+ 15.99492 Da) and phosphorylation (79.96633 Da) was considered in each search. A peptide level false discovery (FDR) rate of less than 1% was used as a threshold for peptide identification using the target decoy strategy. Additional filtering was achieved using a linear discriminant analysis, which combined several parameters into a single probability for each peptide, and these probabilities were used to achieve an FDR of less than 1%. The parameters used for linear discriminant analysis were Xcorr, DCn, peptide mass accuracy and charge state, and peptide length. To determine phosphosite location, we used an Ascore algorithm 35 with a localization score > 13 as the threshold for localization. As 'high-confidence' interactors in a given cell line (Supplementary Table 1 , sheets 1-3, and used for gene ontology analyses presented in Supplementary Table 2) we considered proteins that fulfilled the following criteria: at least five spectral counts for this protein detected in anti-CDK6 immunoprecipitation/mass spectrometry and the ratio K6/K6 + IgG equal to or greater than 0.7 (where K6 is the number of spectral counts for this protein detected in anti-CDK6 immunoprecipitation/mass spectrometry and IgG is the number of spectral counts for this protein detected in IgG mock immunoprecipitation/mass spectrometry).
Gene ontology analysis was performed using the DAVID bioinformatics website (https://david.ncifcrf.gov/). Common interactors were used as the gene set for analysis and all proteins detected in the experiment were used as the background. The results are presented in Fig. 1a , where the x-axis depicts the number of proteins in each category and the y-axis is − log 10 [probability] (Benjamini-Hochberg test); the red horizontal line represents P = 0.01. Human cancer cell lines. AU565, CCFSTTG1, RD, DETROIT562, SCC4, VCAP and WM115 cells were purchased from the American Type Culture Collection (ATCC); SNU213 and SNU466 from the Korean Cell Line Bank (KCLB); and 42MGBA from Deutsche Sammlung von Mikroorganismen und Zellkulturen (DZMZ). HUCCT1 cells were a kind gift from N. M. Bardeesy; EBC1, NCIH1568 and NCIH28 from P. A. Jänne; 786O from W. G. Kaelin; RH41 and RH30 from M. A. Dyer; KOPTK1, MOLT4, RPMI8402, DND41 and MOLT16 from A. T. Look; A172, T98G and U87 from J. Zhao; CORL88, A2780, COLO704 and KURAMOCHI from Novartis Institutes for Biomedical Research; AGS and SW620 from R. A. Shivdasani; MIAPACA2 from A. C. Kimmelman; and 22RV1 from M. Loda. DU145 and LNCAP cells were from T. M. Roberts; and MCF7, ZR75, T47D, HCC1428, CAMA1, HCC1500, BT474, MB453, HCC1419 and EVSAT from K. Polyak. All cell lines were cultured in the recommended media; DND41, KOPTK1, MOLT4, DETROIT562, SCC4, HUCCT1, EBC1, A2780, DU145 and MIAPACA2 cells were tested for mycoplasma contamination and were negative. Nine cell lines were authenticated by STR profiling: MCF7, ZR75, T47D, HCC1428, CAMA1, HCC1500, BT474, MB453 and HCC1419. Isolation and analyses of human T lymphocytes. Peripheral blood mononuclear cells (PBMCs) were obtained from two healthy volunteers with informed consent using a protocol approved by the Dana-Farber Cancer Institute institutional review board. PBMCs were isolated via Ficoll-Paque density gradient. T cells were magnetically selected using the Pan T Cell Isolation Kit (Miltenyi) per the manufacturer's instructions. For T cell stimulation, tissue culture-treated 24-well plates were coated with 0.5 μ g anti-human CD3 (BD Pharmingen) and 0.5 μ g anti-human CD28 (BD Pharmingen) per well diluted in 500 μ l sterile H 2 O and kept at 4 °C overnight. Subsequently, isolated T cells were plated at a density of 2 × 10 6 cells per well in RPMI (Gibco) supplemented with 10% heat-inactivated Fetal Bovine Serum (Clontech) and incubated at 37 °C for 48 h. Two days after initial stimulation, T cell cultures were supplemented with 50 U interleukin 2 (IL-2, RnD) per ml and used for further experiments. To examine the levels of cyclin D3, CDK6, PFKP and PKM2, T cells were cultured with or without IL-2 for 48 h. For apoptosis analysis, cells were treated with 1 μ M palbociclib for 4 days in the presence of IL-2. For cell cycle analysis, T cells were treated with 1 μ M palbociclib for 24 h in the presence of IL-2 before 1 h BrdU pulse. Drug (palbociclib, NAC, MnTMPyP, 6-AN, DHEA, cycloheximide, camptothecin, actinomycin D and etoposide) treatment. Palbociclib (PD-0332991) HCl was purchased from MedChem Express. In experiments gauging the activity of intracellular PFKP or PKM2, formation of PFKP or PKM2 dimers and tetramers, phosphorylation of endogenous PFKP or PKM2, and cell cycle analyses, cells were treated with 1 μ M palbociclib for 24 h. To examine intracellular NADPH, GSH and ROS levels, cells were treated with 1 μ M palbociclib for 24 or 48 h (NADPH, GSH) or 48 h (ROS). In [ 13 C]glucose isotopic enrichment analyses, cells were treated with 1 μ M palbociclib for 24 h (Fig. 2b, Extended Data Fig. 5h-j, 6b , c) or 36 h (Fig. 2a,  Extended Data Fig. 4a-d) . To gauge cell apoptosis, cells were treated with 1 μ M palbociclib for 3-4 days. In experiments shown in Fig. 2g and Extended Data Fig. 5q -t, cells were treated with 0.5 μ M or 1 μ M palbociclib, and apoptosis was assessed after 3 days (Extended Data Fig. 5q-t) or 4 days (Fig. 2g) . To test the impact of PPP inhibition, cells were treated with 50 or 100 μ M 6-aminonicotinamide (6-AN, Sigma), or 100 μ M dehydroepiandrosterone (DHEA, Sigma) and NADPH, GSH, ROS and apoptosis measured as for palbociclib treatment. To inhibit the serine pathway, shRNA against phosphoserine aminotransferase (PSAT1) was applied. The combined effect of inhibiting PPP and the serine pathways was Letter reSeArCH also examined. In these experiments, serine-and glycine-deprived RPMI-1640 medium (Thermo Fisher) was used to culture cells. For combined treatment of breast cancer cells with palbociclib plus low doses of 6-AN, cells were treated with 1 μ M palbociclib together with 6.25, 12.5, or 50 μ M 6-AN. In the experiment shown in Fig. 2f and Extended Data Fig. 4j , cells were treated with 1 μ M palbociclib alone for 2 days. N-acetyl-cysteine (NAC, Sigma) (2.5 mM for DND41; 10 mM for MOLT4; 20 mM for MOLT16) dissolved in RPMI-1640 medium (pH neutralized by NaOH) or 50 μ M MnTMPyP (Millipore) was added to cell culture medium for additional 2 days (together with palbociclib). Cell apoptosis was then analysed using Caspase-Glo3/7 Assay (Promega). In experiments shown in Extended Data Fig. 4h , i, cells were treated with 1 μ M palbociclib for 1 day, then with NAC (2.5 mM for DND41; 10 mM for MOLT4; 20 mM for MOLT16) or 50 μ M MnTMPyP for 1 day (together with palbociclib), and ROS levels were measured. For induction of apoptosis by means other than CDK4/6 inhibition (Extended Data  Fig. 5w, x ), cells were treated with 100 μ M cycloheximide for 24 h (KOPTK1) or 200 μ M for 48 h (MOLT4), 2 μ M camptothecin for 24 h, 10 μ M actinomycin D for 24 h, or 100 μ M etoposide for 24 h. All these compounds were from the Apoptosis Inducer kit (Abcam, ab102480). Doxycycline induction. Doxycycline (2 μ g/ml; DOX, Sigma) was used to induce the expression of PFKP, PKM2, PFKP-S679A or PKM2-S37A in MOLT4 cells. Expression levels of PFKP and PKM2 and levels of NADPH, GSH and ROS were examined after 2 days, and apoptosis after 4 days of induction. Human T-ALL xenograft experiments. All mouse experiments were carried out according to protocols approved by the Institutional Animal Care and Use Committee of the Dana-Farber Cancer Institute. Eight-week-old female NODscid IL-2Rγ null (NSG) mice were purchased from The Jackson Laboratory. Mice were randomly assigned to two experimental groups. One group (n = 12 mice) received 2 × 10 6 KOPTK1 cells expressing wild-type PFKP and wild-type PKM2 (KOPTK1-WT); the second group (n = 12) received 2 × 10 6 KOPTK1 cells expressing phosphomimicking mutants of PFKP and PKM2, PFKP-S679E and PKM2-S37E (KOPTK1-EE). Cells were injected into the lateral tail vein, as described 7 . After 3 weeks, two randomly chosen recipient mice per group were euthanized, and the formation of leukaemia was confirmed by analysing their peripheral blood and bone marrow (CD45 staining followed by FACS analysis, gated on human CD45
+ cells). Once we confirmed that mice developed disseminated leukaemia, the remaining 10 mice from each group were randomly assigned to one of two treatments: 5 mice per group were treated daily, for 5 days, with palbociclib by gastric gavage (150 mg/kg body weight), and the other 5 mice with vehicle only (10 ml/kg). After five days of treatment, mice were sacrificed, and their peripheral blood (cardiac puncture) and bone marrow (from femurs) were collected. Red blood cells were lysed using 1× lysis buffer (BD, 555899) and the remaining cells were stained with annexin V, propidium iodide (PI, eBioscience) and anti-human CD45 antibody (Biolegend, 304032). The fraction of apoptotic human T-ALL cells was determined by FACS analysis of annexin V/PI staining, gated on human CD45 + cells. The sample size was based on our extensive experience in analysing mouse xenografts of KOPTK1 cells 7 . No animals were excluded from the analysis. Animals were randomly assigned to the experimental or treatment groups. The investigators were not blinded to group allocation. According to the Dana-Farber Cancer Institute IACUC regulations, any mice displaying body weight loss equal to or greater than 15% of total body mass, or showing signs of compromised health or distress must be sacrificed. Patient tumour specimen collection and annotation. Patient tumour specimens were obtained from the National Disease Research Interchange, Cooperative Human Tissue Network, Maine Medical Center, and Tufts Medical Center. All patients provided informed consent; samples were procured and the study was conducted under the approval of the institutional review boards of the tissue providers and Novartis. Generation of patient-derived xenografts. The generation of patient-derived xenograft (PDX) models was as described previously 36 . Briefly, 6-8-week-old female athymic nude mice (Crl:NU(NCr)-Foxn1 nu , Charles River Laboratories) were maintained and handled in accordance with the Novartis Institutes for BioMedical Research Animal Care and Use Committee protocols and regulations. Approximately 20-30 mg tissue fragments of patient tumours were implanted subcutaneously into the flank region of athymic nude mice using a trocar. Mice were randomly chosen for implantation of a given tumour. Successfully engrafted tumour models were then passaged. The identity of the established PDXs was confirmed by SNP48 analysis before and after PDX-based pre-clinical trial studies as described previously 36 . Treatment of PDX with ribociclib. Established and genomically characterized PDXs of cutaneous melanoma at passages between p4 and p10 were used; ribociclib treatment was part of a larger study 36 . Mice with tumours (~ 200 mm 3 ) were randomly assigned, on a rolling basis, to ribociclib-treated and vehicle only-treated groups; one tumour-bearing mouse of each model was enrolled per treatment 36 . Mice were treated daily by oral gavage with LEE011 (ribociclib), 250 mg/kg body weight, or with vehicle only starting when the tumour size reached ~ 200 mm 3 , as described 36 . Tumour size was evaluated twice weekly by caliper measurements and the approximate tumour volume was calculated using the formula (L × W × W) × (π /6), where L is the major tumour axis and W is the minor tumour axis. Treatment was terminated when one of the following criteria was met: 1) tumour volume reached 1,500 mm 3 , the maximal volume allowed by Novartis IACUC regulations (maximum allowed total tumour burden per mouse is 10% of body weight); 2) tumour volume increase was > 35% compared to the baseline after 28 days treatment; 3) tumour volume doubled at least twice for slow-growing tumours; or 4) animal met humane end point criteria due to > 20% body weight loss or deteriorated health condition. In the absence of progression or an adverse event, treatment was continued for at least 90 days. The investigators were not blinded to group allocation. For tumour metabolic profiling (Fig. 5, Extended Data Fig. 10i, j) , each primary tumour was implanted into six randomly chosen recipient animals. Tumour-bearing animals were randomly assigned to one of two experimental groups. One group (n = 3 mice) was treated with LEE011 at 250 mg/kg, and the other group (n = 3 mice) with vehicle only, daily for four days. Mice were dosed again on day 5 and tumours were removed 4 h after the last dose, flash-frozen in liquid nitrogen and stored at − 80 °C until they were used for experiments. Statistical analyses. P values were calculated using Student's unpaired two-tailed t-test or the Benjamini-Hochberg test (Fig. 1a and Supplementary Table 2) . The sample sizes were chosen to allow for statistical significance testing assuming a major effect and a small variation. For every analysis the data met the assumptions of the statistical test. In experiments with only three replicates, the normal distribution could not be ascertained. However, the Student's t-test is the appropriate statistical test in those cases. The variation is indicated in all panels by error bars depicting s.d. The variance was similar between the compared groups. Supplementary Fig. 1 . All other data supporting the findings of this study are available from the corresponding author upon a reasonable request.
